The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A synthetic microRNA‐92a inhibitor (MRG‐110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds
Abstract
There is a strong unmet need for new therapeutics to accelerate wound healing across both chronic and acute indications. It is well established that local tissue hypoxia, vascular insufficiency, and/or insufficient angiogenesis contribute to inadequate wound repair in the context of diabetic foot ulcers as well as to other chronic wounds such as venous stasis and pressure ulcers. microRNA‐92a‐3p (miR‐92a) is a potent antiangiogenic miRNA whose inhibition has led to increases in angiogenesis in multiple organ systems, resulting in an improvement in function following myocardial infarction, limb ischemia, vascular injury, and bone fracture. Due to their pro‐angiogenic effects, miR‐92a inhibitors offer potential therapeutics to accelerate the healing process in cutaneous wounds as well. This study investigated the effect of a development stage locked nucleic acid‐modified miR‐92a inhibitor, MRG‐110, in excisional wounds in db/db mice and in normal pigs. In both acute and chronic wounds, MRG‐110 increased granulation tissue formation as assessed by histology, angiogenesis as assessed by immunohistochemistry and tissue perfusion, and wound healing as measured by time to closure and percent closure over time. The effects of MRG‐110 were greater than those that were observed with the positive controls rhVEGF‐165 and rhPDGF‐BB, and MRG‐110 was at least additive with rhPDGF‐BB when co‐administered in db/db mouse wounds. MRG‐110 was found to up‐regulate expression of the pro‐angiogenic miR‐92a target gene integrin alpha 5 in vitro in both human vascular endothelial cells and primary human skin fibroblasts and in vivo in mouse skin, demonstrating its on‐target effects in vitro and in vivo. Additional safety endpoints were assessed in both the mouse and pig studies with no safety concerns noted. These studies suggest that MRG‐110 has the potential to accelerate both chronic and acute wound healing and these data provide support for future clinical trials of MRG‐110.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wetzler, C., Kämpfer, H., Stallmeyer, B., Pfeilschifter, J., & Frank, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00029.x · Cited by 584
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
Chouhan, D., Dey, N., Bhardwaj, N., & Mandal, B. B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119267 · Cited by 522
MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies
Kim, T., & Croce, C. M. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01050-9 · Cited by 407
Metadata
- Authors
- Gallant‐Behm, C. L., Piper, J., Dickinson, B. A., Dalby, C. M., Pestano, L. A., & Jackson, A. L.
- Venue
- Wound Repair and Regeneration
- Publisher
- Wiley
- Published
- 2018-07
- Volume
- 26
- Issue
- 4
- Pages
- 311-323
- ISSN
- 1067-1927 (ISSN-L)
- 1524-475X
- OpenAlex
- W2885395939
- Cited by
- 164
- References
- 1
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.